IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
company -243.50 -59.81 -183.69 -307.12 Financial Position as at December 31 (Unit : Million Baht) 2018 2017 Inc./(Dec.) % Current Assets 423.04 305.00 118.04 38.70 Non-Current Assets 920.89 259.75 661.14
Food & Marketing Public Company Limited (“Company”) would like clarify the revenue from sales and net profit in the consolidated financial statements for the three-month period ended March 31, 2019 as
, 2015; 12.2 The applicant must demonstrate to the SEC Office that the applicant is a qualified auditor, by foreign laws or regulations, to audit the financial statements of a company whose securities are
changed in line with the same direction of the increased in revenue. When comparing Q2- 2022 to Q3- 2021, it found that the change rate of operating expenses is very similar to the change rate of revenue
diminution in value of inventories of Baht 6 million. However, the selling expenses - 3 - increased by Baht 3 million which is in line with the increase in sales revenue. Also, the company recorded employee
allow the Company to produce a wider range of products with higher production efficiency and lower production cost. The greater production capability of the new machinery line will also create more
375.89 100.00 317.58 100.00 - - Cost of Sales Cost of sales of the Company and its subsidiaries soared year-on-year by Baht 32.35 million or 25.87% to Baht 157.39 million in 2019 in line with growth in
2017 PERFORMANCE ANALYSIS (YoY) In 3Q 2017, the Company once again achieved an outstanding top and bottom line performance compared to the same quarter last year supported by; 1) The consolidation of